Watchful waiting versus blood thinners for small lung clots
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial compares close monitoring (“watch and wait”) versus taking the blood thinner rivaroxaban in people with a small type of lung blood clot. It aims to find out whether low-risk patients can safely avoid or reduce anticoagulation while still staying healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have an isolated small lung blood clot (subsegmental pulmonary embolism), diagnosed by testing
- You can sign (or legally have someone sign) informed consent to join the study
- There are no blood clots in the legs or upper arms (like deep vein thrombosis)
- You do not have active bleeding or a high risk of bleeding
- Your kidneys and liver are working well enough for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the body processes a certain type of blood thinner (Xa factor inhibitors) to help doctors find the right dose for each person. If you have a blood clot in your lungs and are on long-term treatment, this trial might help improve your care.
This trial compares three treatments for an intermediate-high risk pulmonary embolism: a minimally invasive clot removal procedure (embolectomy), a low-dose clot-dissolving medication, or standard blood thinning (heparin). The goal is to see which approach works best to prevent worsening while reducing bleeding risks.
This study compares different real-world treatments for a serious but stable type of blood clot in the lungs (called intermediate-high risk pulmonary embolism). It aims to see which treatments work best in everyday patients, including those with other health conditions.
This trial compares two blood-thinning strategies after leg artery surgery or angioplasty to prevent dangerous blood clots. Participants will receive either rivaroxaban plus aspirin or aspirin alone, and researchers will monitor for clots over 30 days.
This trial looks at how long people need blood-thinning medicine after a serious blood clot in the lungs. It might help doctors find the best treatment length for each person.
This trial tests a treatment that uses ultrasound to guide a thin tube (catheter) to deliver clot-busting medicine directly into the blood clot in your lung. It may be an option for people whose clot is serious but not yet causing shock, and who have symptoms that started within the last two weeks.
Hear when a new Pulmonary Embolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.